Latest Share Chat

REMOVE ADS

Allergy Thera. Share News (AGY)

Allergy Thera. Information

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes

Get Live Data

7.50 -0.40 (-5.06%)

Bid:

7.00

Ask:

8.00

Spread: 1.00 (14.286%)

Market Cap: £474.94m

Last checked at -

Intraday Allergy Thera. Share Chart

REMOVE ADS

Allergy Thera. News

EARNINGS AND TRADING: TruFin ups view; Fairview at "inflection point"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

Allergy Therapeutics to explore dual listing in Hong Kong

(Alliance News) - Allergy Therapeutics PLC on Thursday said it is preparing to evaluate a dual primary listing on the Main Board of The Stock Exchange...

LONDON BRIEFING: AstraZeneca earnings rise; J Sainsbury ups guidance

(Alliance News) - AstraZeneca reports higher earnings, J Sainsbury raises its profit guidance and interim dividend while ITV warns of a tough advertis...

Allergy Therapeutics says peanut allergy vaccine trial progressing

(Alliance News) - Allergy Therapeutics PLC said on Thursday that the trial of its short-course peanut allergy vaccine candidate VLP Peanut has had "po...

Allergy Therapeutics shares slump as expects to post revenue decline

(Alliance News) - Allergy Therapeutics PLC on Monday said it expects to report a small decline in earnings during its most recent financial year, as a...

LONDON MARKET OPEN: London stocks climb as miners and gold shine

(Alliance News) - European equities were muted at the market open on Monday, beaten by the FTSE 100 as the index passed the 9,000 mark on a boost from...

Allergy Therapeutics half-year loss narrows on lower expenses

(Alliance News) - Allergy Therapeutics PLC on Monday said talks are underway regarding further financing as it said reduced costs helped trim its half...

Allergy Therapeutics peanut allergy vaccine trial enters final phase

(Alliance News) - Allergy Therapeutics PLC on Thursday said its peanut allergy vaccine trial has entered the final treatment phase.